MPLT

MapLight is a clinical-stage neuro/psychiatry-focused pharma that only began trading on Nasdaq on October 27, 2025, so it carries almost no public history and a fresh-IPO profile. There is no product revenue in either FY2024 or FY2025 — the entire enterprise value rests on preclinical/clinical product candidates whose names, indications, trial phases, and data readouts are NOT in the provided filing. The MD&A's forward-looking section is a wall of pipeline contingencies ('timing, progress and results of our preclinical studies and clinical trials,' 'our ability to successfully receive regulatory approval for, and commercialize, our product candidates'). When the value is 100% pipeline and the pipeline is undisclosed here, the forward risk is genuinely unknowable from this data set — which is the textbook case for 'avoid,' not a bet a self-directed retail investor should size into blind.

The balance sheet is the one bright spot and the reason this isn't an outright 'sell.' The October IPO recapitalized the company: total assets jumped +250% to $480M, stockholders' equity tripled to $458M, and liabilities are a trivial $21.1M (liabilities/equity 0.05x), so there is no debt overhang. But note the cash composition — only $46.7M sits in cash & equivalents; the bulk of the $325M of current assets is in investments. Against FY2025 operating cash burn of -$138M (worsening 75% YoY) and a net loss of -$161M (a doubling from -$77.6M), that liquidity funds roughly two years of operations before the company must raise again. The MD&A explicitly flags 'our ability to obtain additional capital and the sufficiency of our existing cash' as a core risk — meaning dilution is a when, not an if, and it will likely come before any commercial revenue.